Start with the approval answer
The September 28, 2026 record showed that FDA had approved no medicine containing BPC-157. FDA said it found no approved product containing it in any country.
A request to allow pharmacy use was taken back
People asked FDA to put BPC-157 on the ingredient list that allows ordinary pharmacies to prepare medicines to order. FDA’s page marked current April 22, 2026 says those people took their requests back. That page still carries FDA’s concerns about possible harm.
Taking back those requests did not give ordinary pharmacies permission to use BPC-157. The legal record dated September 26, 2026 shows that BPC-157 did not qualify under the rules for ingredients used in ordinary pharmacy compounding. These are rules about what pharmacies may use, rather than laboratory tests on a bottle.
Preparing medicine to order is called compounding.
A meeting is not a change in the rules
In July 2026, FDA staff recommended keeping BPC-157 off the ingredient list for ordinary compounding pharmacies. That recommendation was not a final rule change.
As of September 28, 2026, no official account of the advisory committee’s votes had been published by FDA. A committee’s advice alone cannot change that list; a formal rule change is required.
Read research labels carefully
A research-use label is not FDA approval for treatment.
In letters reviewed on September 26, 2026, FDA said such labels did not excuse marketing unapproved drugs for people.
Ask anyone making a claim of permission to identify the rule and explain how it applies.